Views: 0 Author: Site Editor Publish Time: 2025-03-27 Origin: Site
On March 14, 2025, the Octoparms® II vena cava filter independently developed by Kossel Medtech (Suzhou) Co., Ltd. was approved by the National Drug Administration (NMPA). (registration number is 20253130576). In addition, the Seledora® coronary scoring balloon catheter developed by the subsidiary Mixin Medtech was also approved by the National Medical Products Administration (NMPA) today. (registration number is 20253030586).
Vena Cava Filter
Three core advantages upgraded
The stability upgraded
Retrieval hook is smooth to reduce delivery resistance
Raise and widen the balance arm to improve long-term stability
New anchoring hook design, anti-displacement, anti-penetration
Diamond-shaped filter can effectively block thrombus of 4mm and above
The specification upgraded
The delivery system upgraded
Releasable and interlocking arm design, to achieve controlled release in a transjugular way
Double markers with a space of 30mm, help measure the diameter of the inferior vena cava
The sheath is braided to enhance support and bending resistance and establish a stable path
The sheath end is thread design, anti-shift, easy to approach
The delivery system
Octoparms® vena cava filter, clinically proven, is a domestic umbrella-shaped filter with excellent performance, it has been recognized by nearly 2,000 hospitals in China since its launch, benefiting tens of thousands of patients.
Coming out of the clinic need and serving the clinic need, Octoparms® Ⅱ, an upgrade of the Octoparms® vena cava filter, will be more widely used and accepted for the benefit of more patients